Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionDaiwa Securities Group Inc.
Latest Disclosed Ownership67,539 shares
Latest Disclosed Value $ 30,158,865
Daiwa Securities Group Inc. reports 4.33% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Daiwa Securities Group Inc. filed a 13F-HR form disclosing ownership of 67,539 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $30,158,865 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 70,595 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -4.33% during the quarter. The current value of the position is $28,929,655 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 67,539 -3,056 -4.33 30,159 94,143.75 0.0867
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 70,595 3,368 5.01 32 23.08 0.1022
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 67,227 -8,605 -11.35 26 -21.21 0.0889
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 75,832 4,600 6.46 34 -2.94 0.1246
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 71,232 5,504 8.37 35 30.77 0.1460
2025-02-07 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 65,728 7,861 13.58 26 0.00 0.1182
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 57,867 14,194 32.50 27 30.00 0.1243
2024-08-07 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,673 -255 -0.58 20 11.11 0.1089
2024-05-02 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,928 6,941 18.77 18 20.00 0.1036
2024-01-31 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,987 351 0.96 15 25.00 0.0936
2023-11-01 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 36,636 5,572 17.94 13 20.00 0.0908
2023-07-31 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,064 106 0.34 11 11.11 0.0723
2023-05-02 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,958 1,296 4.37 10 12.50 0.0678
2023-02-06 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,662 388 1.33 9 -99.91 0.0658
2022-11-02 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,274 1,145 4.07 8,476 6.94 0.0704
2022-08-09 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,129 1,582 5.96 7,926 14.41 0.0606
2022-04-29 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,547 3,372 14.55 6,928 36.14 0.0320
2022-02-03 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,175 1,483 6.84 5,089 29.33 0.0299
2021-11-05 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,692 1,899 9.59 3,935 -1.40 0.0259
2021-08-06 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,793 932 4.94 3,991 -1.53 0.0269
2021-05-03 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,861 1,698 9.89 4,053 -0.07 0.0302
2021-02-04 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,163 -28,290 -62.24 4,056 -67.21 0.0314
2020-11-02 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 45,453 14,382 46.29 12,369 67.31 0.1120
2020-08-11 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,071 0 0.00 7,393 0.00 0.1559
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,071 18,639 149.93 7,393 171.60 0.0767
2020-01-31 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,432 4 0.03 2,722 29.25 0.0225
2019-11-04 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,428 622 5.27 2,106 -2.73 0.0178
2019-07-24 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,806 61 0.52 2,165 0.23 0.0191
2019-04-26 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,745 858 7.88 2,160 19.73 0.0189
2019-02-05 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,887 540 5.22 1,804 -9.53 0.0173
2018-11-01 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,347 533 5.43 1,994 19.54 0.0167
2018-07-30 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,814 -301 -2.98 1,668 1.15 0.0131
2018-05-02 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,115 2,553 33.76 1,649 45.54 0.0132
2018-02-06 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,562 1 0.01 1,133 -1.48 0.0080
2017-11-02 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,561 391 5.45 1,150 24.46 0.0079
2017-07-28 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,170 220 3.17 924 21.58 0.0060
2017-05-02 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,950 650 10.32 760 63.79 0.0048
2017-02-01 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,300 250 4.13 464 -12.12 0.0030
2017-01-10 2016-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,050 250 4.31 528 5.81 0.0032
2016-11-04 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,050 528
2016-07-25 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,800 0 0.00 499 8.24 0.0030
2016-05-12 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,800 -32,400 -84.82 461 -90.41 0.0029
2016-02-04 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 38,200 32,600 582.14 4,807 724.53 0.0318
2015-11-10 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,600 0 0.00 583 -15.63 0.0041
2015-08-05 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,600 0 0.00 691 4.54 0.0049
2015-05-12 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,600 -20,470 -78.52 661 -78.66 0.0044
2015-02-13 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,070 17,430 201.74 3,097 219.28 0.0219
2014-11-12 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,640 2,140 32.92 970 57.72 0.0073
2014-08-13 2014-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,500 0 0.00 615 33.70 0.0046
2014-08-13 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,500 615
2014-05-14 2014-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,500 0 460 0.0036
2014-05-15 2014-03-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 6,500 0 0.00 460 -4.76 0.0036
2014-05-13 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,500 460
2014-02-13 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,500 0 0.00 483 -2.03 0.0041
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,500 0 0.00 493 -5.19 0.0039
2013-08-16 2013-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,500 6,500 520 0.0039
2013-08-13 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,500 520
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.